Superior until it was not: Regulatory closing risk and the superior-proposal determination in Novo Nordisk’s bid for Metsera

Sašo Kraner is a Partner at White & Case LLP.  The following article is based on the author's analysis of publicly available transaction documents and information. The author is deeply grateful to his White & Case colleagues Thomas W. Christopher, Michael Deyong, Stephen Fraidin, and Rebecca Farrington, and to Géraldine Abegg-Babin, Global Head of Competition & FDI at ASML, for their generous review, insights, and thoughtful comments; any errors remain the author's alone. The views expressed are the author's own and do not represent those of White & Case LLP or any client. The illustrative valuation is provided for analytical purposes and is not investment advice. This article is for informational purposes only. It is not legal or other professional advice on any specific facts or circumstances, and neither its publication nor its receipt creates an attorney-client relationship.

In the fourth quarter of 2025, Novo Nordisk A/S ("Novo") intervened as an interloper in the acquisition of Metsera, Inc. ("Metsera"), a clinical-stage developer of obesity and metabolic therapies that had entered into a merger agreement to be acquired by Pfizer Inc. ("Pfizer"). Novo offered a higher headline price than Pfizer, together with a structure designed to neutralize the greater antitrust risk its offer carried. The structure was less novel than it first appeared. Novo ultimately abandoned the proposal after the staff of the Federal Trade Commission (the "FTC") signaled that it was inclined to recommend a challenge and Pfizer commenced actions in two courts seeking to block the transaction. Pfizer raised its offer in successive steps until it matched Novo's final proposal in both amount and composition. Once the headline figures converged, Metsera's board concluded that Novo's structure carried unacceptable legal and regulatory risk relative to the deal certainty Pfizer offered.

The contest reduces to two questions, neither unique to it. The first is valuation: what is a bid worth when its completion depends on antitrust clearance? Where competing headline prices converge, as they did here, that question decides the contest. Antitrust objections to a bid's structure bear on its value rather than raising a threshold question separate from price. The second is fiduciary duty: when may a target board accept the riskier of two bids, and on what terms, under the contractual superior-proposal standard and the limits Delaware places on deal protections?

The final proposals were identical in amount and composition; they differed in structure, in timing, and in the probability that each would be consummated. This article examines that contest and the deal mechanics and structures that decided it, and their implications for the market for corporate control when regulatory risk, rather than price, is the decisive variable.

Key Points

• Antitrust risk is a substantive component of deal value, and where competing bids converge on headline price, it tends to become the decisive variable. Nor is the resulting valuation discount confined to antitrust: the same arithmetic applies to any approval on which closing depends, whether the relevant regulator supervises insurance, banking, communications or energy.
• Novo's non-voting preferred structure allowed roughly three-quarters of the proposed consideration (valuing a contingent value right, or CVR, at its maximum), and half of Metsera's equity, to change hands before any antitrust review. The HSR rules, which disregard any transaction or device employed to avoid a filing obligation and test reportability against the substance of the transaction as a whole, undermined the certainty the structure was designed to offer. A filing obligation may therefore exist notwithstanding the structure's form.
• The regulatory-likelihood prong of the contractual "superior proposal" standard calls for a genuine probabilistic assessment, and for care in the sequencing and framing of the board's findings rather than a nominal acknowledgment that clearance is uncertain.
• Had Metsera entered into a merger agreement with Novo, the Delaware courts might have had to decide whether the transaction structure impermissibly precluded rival and superior offers under Unocal/Unitrin enhanced scrutiny and under Omnicare and its progeny. Specifically, the question would have been whether the mandatory redemption of the preferred stock at a fixed cost despite fluctuations in the value of the target, which a competing bidder's transaction would have obliged Metsera to fund, made any competing bid effectively uneconomical or otherwise impractical.¹  The Metsera board did not find the Novo proposal wanting; it three times determined that the proposal was superior. The contest ended instead because Pfizer matched Novo's price before any Novo agreement was signed, and because the Metsera board's final determination rested, for the reasons discussed below, on the transaction's legal and regulatory risks rather than on its price.
• Although the final Pfizer and Novo prices were identical, the bids were not equal in value. The Novo proposal was worth what it promised only if the upfront structure survived legal challenge and the back-end merger cleared antitrust review, and the antitrust objections put both in doubt. A board weighing that uncertainty could reasonably conclude that Pfizer's nearly certain package was worth more after adjusting for risk.
• Novo's aggressive price competition forced Pfizer to raise its price repeatedly, resulting in substantially greater value for Metsera's stockholders than Pfizer had originally offered.

Background: The Contest

Metsera is a clinical-stage developer of injectable and oral therapies for obesity and metabolic disease; its initial public offering priced at $18.00 per share in January 2025. On September 22, 2025, Metsera and Pfizer announced a definitive agreement and plan of merger, dated September 21, 2025 (the "Pfizer Agreement"), under which Pfizer would acquire Metsera for $47.50 per share in cash plus one non-tradeable contingent value right (a "CVR") of up to $22.50 per share, payable upon the achievement of three specified clinical and regulatory milestones, for total consideration of up to $70.00 per share. The Pfizer Agreement contained customary deal protections: a no-solicitation covenant subject to a fiduciary out keyed to a defined "Superior Company Proposal," a matching right exercisable over four business days (two business days for subsequent modifications), and a company termination fee of $190 million. The parties filed their premerger notifications under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") on October 8, 2025, and the FTC granted early termination of the waiting period effective October 31, 2025.²

On October 30, 2025, Metsera disclosed an unsolicited acquisition proposal from Novo, which the board had determined on October 29 constituted a "Superior Company Proposal." The proposal contemplated aggregate consideration of up to $77.75 per share, approximately $9.1 billion, structured in two steps. In the first step, upon signing and without antitrust clearance, Novo would pay approximately $6.5 billion to subscribe for newly issued non-voting convertible preferred stock representing fifty percent of Metsera's post-issuance fully diluted share capital, and Metsera would declare a special dividend (the "Dividend," as adjusted in subsequent proposals) of $56.50 per share of common stock, with a record date ten days following signing and payment shortly thereafter, distributing the subscription proceeds to its common stockholders. In the second step, following stockholder approval and antitrust clearance, Novo would acquire the outstanding common stock for one CVR of up to $21.25 per share. Novo would pay Metsera's $190 million termination fee to Pfizer upon termination of the Pfizer Agreement. The proposed Novo merger agreement provided for a company termination fee of $227 million plus reimbursement of the $190 million Pfizer termination fee and an outside date of twenty-four months from signing, extendable at Novo's election to twenty-seven and then thirty months. It also provided for mandatory redemption of the preferred stock, at Novo's aggregate subscription price in cash, upon the closing of a topping-bid transaction entered into through the fiduciary out or of an acquisition following a failed stockholder vote.³ Because the preferred stock would carry no present voting rights and would be convertible only at the holder's election, to the extent permitted by applicable law (and automatically upon transfer to a non-affiliate of Novo), the first step was structured to require no HSR Act filing: roughly three-quarters of the consideration, and fifty percent of the equity, would change hands before any regulatory review.

The premise. The point of the design was jurisdictional: to relieve the upfront step of any duty to notify. The HSR Act conditions premerger notification and the statutory waiting period on acquisitions of voting securities or assets above the size-of-transaction threshold. Convertible preferred that carries no present vote is nonetheless a "voting security" under the rules, which reach securities entitling the holder to vote at present or upon conversion. But the acquisition of convertible voting securities is exempt from notification by rule, and conversion is itself a separate, potentially reportable acquisition. The clearance contingency bore on the questions of beneficial ownership and avoidance discussed below rather than on the exemption.⁴ The mechanism is an exemption from reporting rather than an exclusion from the definition. The more searching inquiry is whether, looking through form to substance, the acquirer obtains beneficial ownership of the underlying voting securities or assets, a question the non-voting label does not by itself answer. Novo's theory was that the upfront step required no filing and carried no clearance risk, so that the greater part of the consideration could be delivered with certainty and only the back end would remain subject to the agencies. The premise is sound as far as it goes, but, as discussed below, the absence of a filing obligation is not the absence of antitrust exposure.

The ensuing contest proceeded in parallel before the board, in two courts, and at the FTC. On October 31, 2025, Pfizer filed suit in the Delaware Court of Chancery against Metsera, its directors, and Novo, seeking, among other relief, a temporary restraining order against termination of the Pfizer Agreement. On November 3, it filed a second action in the United States District Court for the District of Delaware asserting claims under Section 7 of the Clayton Act and Sections 1 and 2 of the Sherman Act against Novo, Metsera, and Metsera's principal stockholders. Also on November 3, Pfizer delivered a revised offer of $60.00 in cash plus a CVR of up to $10.00, unchanged in headline value at $70.00. The revision was conditioned, among other terms, on an increase in the termination fee to $242 million and on a public statement by Metsera that the Novo proposal presented unacceptably high risks and was unviable. On November 4, Novo increased its proposal to $62.20 in cash upfront plus a CVR of up to $24.00, up to $86.20 per share (approximately $10.0 billion), and the board that day determined that the revised proposal constituted a "Superior Company Proposal," its second such determination. The same day, the Director of the FTC's Bureau of Competition sent the letter discussed below to counsel for Novo and Metsera. On November 5, following hearings on November 4 and 5, the Court of Chancery denied Pfizer's application from the bench, declining to enjoin an auction that was, as the court observed during the hearings, generating additional value for stockholders. Pfizer matched the $62.20 and $24.00 terms the same day. On November 6, Novo increased its proposal a final time, to $65.60 in cash plus a CVR of up to $20.65, up to $86.25 per share (in this final form, the "Novo Proposal"), and the board made its third superior-proposal determination.

On November 7, the Bureau of Competition advised Metsera's counsel that it was inclined to recommend that the FTC bring suit in federal court with respect to the first step of the Novo structure. Later that day, Pfizer delivered a proposal on economic terms identical to the Novo Proposal ($65.60 in cash at closing plus a CVR of up to $20.65), which by its terms expired eight hours after delivery. The board determined that the Novo transaction presented unacceptable legal and regulatory risk to Metsera and its stockholders. Metsera and Pfizer then executed an amendment to the Pfizer Agreement providing for the increased consideration, a termination fee of $265 million, and mutual releases. Novo announced on November 8 that it would not increase its proposal. Metsera's stockholders approved the merger on November 13, 2025, with 99.98 percent of the votes cast in favor, and the merger closed the same day. Both Pfizer actions were dismissed by stipulation in February 2026.

Pricing the Antitrust Risk

The starting point is familiar to practitioners but is often stated too loosely.⁵  Because target stockholders in a public-company merger receive the consideration only at closing, and closing is conditioned on regulatory clearance, the value of a share while the transaction is pending is not the deal price but a probability-weighted figure. If D denotes the deal consideration, p the probability that the transaction is consummated, and B the value the stock would command if the transaction failed (in the ordinary case the unaffected or standalone trading level rather than zero), the risk-adjusted value of the share is approximately pD + (1 - p)B. The discount to the deal price is therefore (1 - p)(D - B): the probability of failure multiplied by the spread between the deal price and the level to which the stock would revert. The common shorthand that a contingent bid is worth its face amount multiplied by the probability of closing assumes a downside of zero; by omitting the (1 - p)B term, it overstates the discount, and does so materially where the unaffected price is high, as it was here.

The framework requires two refinements before it can be applied. First, because the consideration is received only at closing, it must be discounted to present value over the expected time to clearance. The proposed Novo agreement fixed an outside date of twenty-four months from signing, extendable at Novo's election to twenty-seven and then thirty months,⁶ a longer-than-usual horizon that deepens the discount independently of the probability of success. The principal source of that delay is the second request, which the back-end acquisition (the purchase of a nascent rival by the leading incumbent) would very likely have drawn and which an outside date of that length is designed to accommodate. The Pfizer transaction, by contrast, received early termination of the waiting period within weeks of filing. Second, the market ordinarily expresses this discount as the merger-arbitrage spread (the difference between the deal price and the prevailing trading price), which widens as the perceived probability of failure rises or the expected timeline lengthens. Where part of the consideration is a CVR, the milestone risk embedded in the "up to" figure is a distinct layer: the antitrust discount operates on the closing-contingent consideration, and the milestone discount applies to the CVR alone.

The size of the discount is bidder-specific: it varies with the anticompetitive effect of each proposed business combination. An acquirer with no horizontal overlap ordinarily faces less substantive risk and can credibly offer a high probability of clearance, whereas an acquirer that already leads the relevant market presents the strongest case for a challenge under Section 7 of the Clayton Act,⁷ so that p is lower and the discount correspondingly larger. The lower risk that attends the absence of a horizontal overlap is a tendency rather than a rule: vertical and conglomerate cases can prove considerably more demanding than the label suggests. The Metsera contest illustrates the bidder-specific point in unusually clean form. Pfizer, whose own obesity program had not reached the market, could present its agreement as bearing little antitrust risk, and the FTC in fact granted early termination of the waiting period on October 31, 2025. Novo, whose semaglutide franchise (Wegovy and Ozempic) makes it a leading incumbent in obesity and diabetes care, presented the paradigmatic Section 7 concern: the acquisition by a market leader of one of its more advanced emerging competitors. The economic literature labels the limiting case, in which an incumbent acquires a nascent rival in order to discontinue its development, a "killer acquisition."⁸ The term is imprecise here: the concern did not depend on proof of intent, and because Metsera had no marketed product, the theory was one of nascent competition, which is harder to sustain. That qualification bears on the contestability discussed below. The two final proposals were identical in both amount and composition: each comprised $65.60 in cash plus a CVR of up to $20.65, up to $86.25 per share. Where the nominal figures converge exactly, the comparison reduces entirely to the risk the transaction will not close: the choice between the two bids was, in substance, a choice between their respective probabilities and timelines. On that footing, the Metsera board described the amended Pfizer transaction as "the best transaction for shareholders, both from the perspective of value and certainty of closing,"⁹ a characterization that names the value-maximizing criterion rather than a mere preference for caution.

The following illustration applies the framework to the two final proposals. The consideration figures are those the parties disclosed; the probabilities, the discount rate, the assumed CVR realization, and the unaffected price are stated assumptions, included to make explicit the variables on which the comparison turns rather than to predict an outcome.

Illustrative Risk-Adjusted Value Per Share

Unaffected price taken as approximately $33, Metsera's September 19, 2025, close, to which the parties' disclosed premiums refer (about 133% for Novo's first proposal and 159% for its amended proposal); discount rate 8% per year; CVR valued at 40% of face and applied symmetrically, the milestone terms being substantially similar across the two bids. Time to closing is each agreement's fully extended outside date. The probabilities are assumptions rather than predictions.¹¹

The Pfizer transaction in fact closed on November 13, 2025,¹² the same day as the stockholder vote and within a week of the final agreement, so the nine-month outside date materially overstated its timeline. On the roughly eight-week timeline on which it actually closed, Pfizer's risk-adjusted value is approximately $70.

The illustration yields two results, one expected and one not. First, even on each agreement's worst-case outside date, the risk-adjusted values diverge by roughly three dollars per share notwithstanding the identity of the headline figures, and by roughly six dollars measured against the timeline on which the Pfizer transaction in fact closed. That divergence confirms that where the nominal numbers are equal, the difference in value is attributable to the antitrust risk. Second, the Novo figure falls slightly below its front-loaded cash component. The $65.60 payable shortly after signing protects the downside only if it is in fact paid and retained: the probability that the structure fails is concentrated in the window before payment, whether through an injunction against the first step or a successful challenge to the Dividend under Delaware's legal-capital (capital-maintenance) rules, and the FTC's letter expressly contemplated rescission (including the refund of monies paid upfront). In those scenarios the stockholders revert to standalone value with no cash in hand, and the expected value of the contingent back end is slightly more than offset by that prospect, so the proposal as a whole was worth no more than its upfront cash. The structure's advertised certainty was itself contingent. The Novo result is, in addition, highly sensitive to the two probabilities that drive it. If one assumed instead that the structure was secure (on the order of a ninety-five percent chance of legal validity), then even with the conditional probability of clearance reduced to fifty-five percent, the unconditional probability that the back end would pay would rise from forty-five percent to over fifty-two percent, and the Novo risk-adjusted value would rise to approximately $73, exceeding even the Pfizer value on the timeline on which that transaction actually closed. The valuation of the Novo Proposal thus turns almost entirely on the likelihood that the structure would survive judicial scrutiny and that the back-end acquisition would receive antitrust clearance, the very inputs the antitrust objections placed in doubt.

Market prices corroborate the comparison. On November 4, with the amended Novo proposal outstanding and the FTC letter disclosed, Metsera's common stock closed at $73.18, approximately fifteen percent below the proposal's nominal value of $86.20. On November 10, following Novo's withdrawal and with only the Pfizer transaction pending (closing was three days away), the stock closed at $70.87, implying a value for the $20.65 CVR of approximately $5.27, roughly one-quarter of its face amount. The trading record supports the direction of both discounts applied in the illustration: a completion-risk discount while the contest was pending, and a substantial CVR discount after it concluded, though the market's valuation of the CVR fell materially below the forty percent the illustration assumes.

Why the Probabilities Were Low

The premium that made the Novo Proposal attractive rested on the proposition that the upfront step did not require an HSR filing and that the business combination would ultimately receive antitrust clearance. Two antitrust risks threatened that proposition, and they are easily run together. The first is structural and procedural: whether the upfront step could proceed without an HSR filing at all, or would instead be treated as an avoidance device and expose the parties to the risk of an injunction or, if the transaction were allowed to close, rescission and penalties. The second is substantive: whether the eventual combination would be challenged and blocked under Section 7. The substantive risk is the one that generally creates the antitrust discount, but on these facts the upfront step compounded it, as did a separate question under Delaware's legal-capital (capital-maintenance) rules noted below.

The avoidance rule. The HSR rules disregard any transaction or device "entered into or employed for the purpose of avoiding" a filing obligation and test reportability against the substance of the transaction as a whole.¹³

Antitrust authorities had already confronted a closely analogous structure, and Novo's design was, in form, a variation on that template rather than a novelty. In connection with Canon's 2016 acquisition of Toshiba Medical Systems Corporation, a medical-imaging business, Toshiba restructured the target's capital into a single non-voting share plus options and sold them to Canon for the full purchase price of approximately $6.1 billion. The voting stock was placed for a nominal sum in a special-purpose entity pending regulatory clearance. The arrangement allowed Toshiba to recognize the sale proceeds before its fiscal year-end without first filing. In the United States, the Department of Justice, on a referral from the FTC, alleged a violation of the HSR Act's notification and waiting-period requirements, invoking the avoidance rule and reasoning that the upfront transfer of the full price had given Canon the present rights, benefits, and risks of beneficial ownership before any filing, regardless of the non-voting label.¹⁴ Novo's design shared those salient features: a large upfront payment, a non-voting characterization of the instrument received, and a sequencing designed to place economic value in the acquirer's hands before any premerger notification. The difference was one of degree: Novo's subscription reached only half the target's equity rather than the whole of it, leaving the controlling back end to be cleared. The remaining distinctions Novo could draw were real but did not clearly set it apart. First, unlike in Canon/Toshiba, the upfront subscription proceeds would have been distributed immediately to Metsera's common stockholders as a dividend rather than retained by the company, so Novo would not have sat atop Metsera's accumulated cash during the interim period. Second, Novo could argue an independent commercial rationale: certainty of delivery of upfront cash to Metsera's stockholders at a time when the Pfizer transaction was still pending, rather than a designed evasion of the filing obligation. But the avoidance rule's substantive inquiry weighs independent rationale against the economic consequences of the rights acquired, and where those consequences are a present half-ownership interest in a direct competitor, the non-voting label and the Dividend passthrough may not suffice to answer it.

The Bureau of Competition's letter of November 4, 2025, confirmed that the FTC's staff read the structure in precisely this way: it would transfer to Novo "significant rights, benefits, and risks" before any premerger review. The letter stated the principle in general terms: firms cannot evade review by "disaggregating an acquisition into multiple steps and deferring the HSR filing to the end," that is, until "after potentially anticompetitive harms have already occurred." That communication was an informal staff letter rather than a complaint, a consent order, or a judicial ruling; it bound no one, but it signaled credible enforcement risk. The letter expressly took no position on whether the combination would lessen competition on the merits. The letter also warned that proceeding without a filing could expose the parties to daily civil penalties, to rescission of the transaction (including the refund of monies paid upfront), and to potential liability for the officers or directors involved.¹⁵

The exemption would have relieved only the notification obligation. Section 7 of the Clayton Act reaches the acquisition of "any part" of a company's stock, including a non-voting minority interest, without regard to whether the acquisition was reportable, and consummation is no defense; the FTC could have challenged Novo's fifty-percent preferred position directly, whether before or after it was acquired. In this sense the absence of a filing obligation is not the absence of antitrust exposure: the first step was, at most, exempt from reporting; it was never exempt from Section 7.¹⁶

Gun-jumping. The same letter raised the operating restrictions the proposed Novo agreement would impose during the interim period, including the consent requirement for capital expenditures exceeding $2.5 million in the aggregate for any calendar year and limits on employee retention. Until closing, the acquirer may not assume operational control of the target. Two distinct doctrines apply. HSR gun-jumping bars the premature acquisition of beneficial ownership or assumption of operational control before the waiting period expires and carries civil penalties accruing for each day of violation. Section 1 of the Sherman Act separately reaches pre-closing coordination between competitors that rises to an unlawful agreement. Covenants that preserve value are permitted under both, but covenants that constrain ordinary-course competitive conduct are not. Novo could characterize the cap and the retention limits as ordinary going-concern protections, but for a clinical-stage company whose value resides in its pipeline and its personnel, a $2.5 million annual capital-expenditure cap and constraints on retaining scientists may be hard to defend as mere value preservation.¹⁷

These objections did not reduce the headline price; they reduced the probabilities that the structure would survive challenge under the avoidance rule and that the business combination would survive substantive antitrust scrutiny. Those two probabilities are, as the illustration above shows, the variables on which the value of the Novo Proposal principally depended. The substantive Section 7 question was contestable: the obesity field is crowded with well-funded entrants, and the agencies' nascent-competition theories have an uneven litigation record,¹⁸ so a confident prediction that the back end would be blocked on the merits would have been premature. The back-end acquisition would also have required foreign clearances (for a pre-revenue target, likely under transaction-value regimes such as Germany's and Austria's rather than the EU Merger Regulation's turnover thresholds) that would have lengthened Novo's timeline and, given its market position, carried substantive risk of their own, an asymmetry that fell on Novo alone. Nor was the avoidance-rule exposure a uniquely American concern: in Canon/Toshiba the European Commission fined Canon €28 million for implementing a concentration before clearance on materially the same warehousing structure, in which the target is parked with a nominally independent interim buyer while the true acquirer pays substantially the full price at the outset and takes ownership only after clearance arrives. In any jurisdiction where the back-end acquisition required antitrust clearance, the upfront step would have risked parallel violations whatever its treatment under the HSR rules. What was harder to discount was the structural and procedural exposure, and the structure in fact failed on that exposure, on the Delaware Dividend question, and on a matched topping bid, rather than on a merits challenge. The discount the structure was designed to remove thus reappeared, less as substantive blocking risk than as legal and execution risk, and it was on this basis that the board concluded that the Novo Proposal carried "unacceptably high legal and regulatory risks."¹⁹

The Delaware-Law Overlay

If the value of the Novo Proposal is the first analytical theme, the constraints Delaware law imposed on a board that wished to accept it are the second. The Metsera board never had to confront them because Pfizer matched and the matter was resolved, but they are worth examining, both because the matching contest could as easily have gone the other way and because the configuration will recur: a market-leading interloper advancing a structurally novel higher bid against a well-priced incumbent deal. What follows is counterfactual: had Pfizer exhausted its matching rights and declined to improve further, what would the directors' duties have required?

Because Metsera was being sold for cash and contingent cash consideration, the board's task was governed by the value-maximizing duties articulated in Revlon and QVC,²⁰ which required the board to seek the best value reasonably available: a standard that tests the reasonableness of the board's process and does not demand the highest conceivable price. Here that standard permitted the board to use a competing bid as leverage. That duty frames the three questions the contest presents.

Whether the Novo Proposal was a "superior proposal." Under the Pfizer Agreement, Metsera's board could terminate in favor of a competing proposal only if that proposal satisfied the contractual definition of a "superior proposal." Such definitions characteristically incorporate deal certainty: they ask not only whether the competing consideration is higher but whether the competing transaction is reasonably likely to be consummated, including the likelihood of obtaining required regulatory approvals. The qualification exists precisely because a nominally higher bid that may never close is not, in substance, superior. That standard was explicit on the face of the deal documents: the proposed Novo agreement defined a "Superior Proposal" to require the board to weigh, among other things, "the probability that such Takeover Proposal or the Transactions will be consummated," and the Pfizer Agreement's parallel definition of a "Superior Company Proposal" was to the same effect.²¹ That the definition folds deal certainty into the judgment of superiority resolves what would otherwise look like a contradiction in the board's own record. Metsera's board found the Novo bid superior three times (on October 29, November 4, and November 6, the latter two on or after the date of the FTC's letter), and then, on November 7, found it to carry "unacceptably high legal and regulatory risks," including the risk that the Dividend might never be paid. The findings stand in sequence rather than in conflict. The letter did not end the auction: the Metsera board made two further superiority determinations and, within four days, obtained from Pfizer an increase of more than sixteen dollars per share. What converted risk into disqualification was the Bureau of Competition's statement that it was inclined to recommend suit against the first step, delivered the same day as a Pfizer proposal of identical value and composition. Once the prices were identical, risk was the only comparator left, and any increment of legal risk became determinative. The Novo Proposal was superior until it was not.

Two points temper any criticism of Metsera's board. First, declaring a proposal superior did not terminate the Pfizer Agreement; it triggered Pfizer's right to match, and Metsera never did terminate, so the mechanism operated as designed and Pfizer's improved bid prevailed. Even had Pfizer declined to improve its offer further, the superior finding would not by itself have required termination; exercising the fiduciary out was a separate step demanding independent justification under the Pfizer Agreement. Second, a good-faith determination of this kind, made with the advice of counsel and financial advisors and expressly weighing Pfizer's adjustments, is the sort of determination a court would likely test for reasonableness under the Revlon enhanced scrutiny standard, though as against the Pfizer transaction the operative question would remain contractual: whether the determination satisfied the agreement's definition.

The standard of review that would govern any post-closing fiduciary challenge reinforces that reading of the record. Because Metsera's stockholders approved the Pfizer merger by a fully informed vote, post-closing fiduciary review would likely proceed under the business judgment rule. Corwin held that a merger approved by an uncoerced, fully informed majority of disinterested stockholders is entitled to business judgment deference notwithstanding that the board's pre-vote conduct would otherwise draw enhanced scrutiny.²² Pfizer's complaint did put one predicate in issue, alleging that Metsera's principal stockholders, holding approximately 37.6 percent of the common stock and four of the six board seats, were Metsera's controlling stockholders. The allegation matters because a conflicted-controller transaction is tested for entire fairness and is not cleansed by Corwin. But this does not appear to have been such a transaction. It was a sale to an unaffiliated third party in which those investors received the same per-share consideration as every other holder, with no controller standing on both sides of the transaction and, apart from the indemnification addressed below, no apparent benefit the other stockholders did not share, so Corwin's cleansing should apply. The 2025 amendments to Section 144 of the Delaware General Corporation Law ("DGCL"), sustained against constitutional challenge in February 2026, point in the same direction. Even if the group's roughly 37.6 percent voting stake and four of six board seats arguably met the newly codified definitions of a controlling stockholder and control group, the statute's controller safe harbors (and the entire-fairness review they displace) attach only to a "controlling stockholder transaction": an act or transaction between the corporation and the controller or control group, or one from which the controller receives a financial or other benefit not shared with the stockholders generally.²³ An arm's-length sale to a third party on terms shared ratably with all common stockholders would not appear to satisfy either prong. Accordingly, under Corwin, the approval of the transaction by a fully informed, uncoerced majority of disinterested stockholders should suffice to avoid review under the entire fairness standard.

Pfizer's further contention, that the directors breached the duty of loyalty by accepting a self-interested indemnification from Novo, is best understood as an attempt to plead director self-interest that would render both statutory exculpation and Corwin cleansing unavailable.²⁴ The argument was twofold: by accepting the indemnification, the directors received a non-ratable benefit that gave rise to a claim for breach of the duty of loyalty for which exculpation was not available under DGCL Section 102(b)(7); and the benefit, if material and inadequately disclosed, could undermine the fully informed character of the stockholder vote on which Corwin cleansing depends. But the indemnity was disclosed, never became operative because no Novo agreement was ever executed, and was not shown to have reduced what the stockholders received. Whether that record would support the non-exculpated loyalty or bad-faith claim such a theory requires is at least doubtful.

Corwin's reach also explains why the two courses open to the Metsera board, had Pfizer declined to match, did not carry equal exposure. Declining Novo and proceeding with Pfizer would have left only a stockholder's Revlon claim that the Metsera board passed on a “superior” bid, which the fully informed vote cleanses under Corwin. Terminating for Novo would instead have exposed Metsera to Pfizer's contractual claim that the superior-proposal determination was invalid and the termination wrongful, a claim Corwin does not reach.²⁵ The exposure was therefore real but one-sided, and the likeliest resolution would have been a return to Pfizer for further negotiation, the course most consistent with both the contractual machinery and the board's own risk finding, rather than an exercise of the fiduciary out. The Pfizer Agreement itself settled how much weight that asymmetry could bear. If Metsera terminated to accept a superior proposal and paid the $190 million fee, the fee was the end of the matter: the agreement made its payment Pfizer's sole and exclusive remedy for the failure of the merger to close. That exclusivity gave way in two situations: fraud, and a breach both willful and material, with the agreement confining the second to deliberate conduct undertaken with knowledge that it would break the contract. A termination resting on a judgment reached in good faith, even a judgment a court later held mistaken, would have cost Metsera the fee and nothing more in damages. A termination resting on a determination the board knew was invalid would have exposed Metsera to Pfizer's full expectation damages, with no cap. A related question, whether damages for a broken merger may be measured by the premium the stockholders lost, was litigated in Consolidated Edison, Inc. v. Northeast Utilities and revisited in Crispo v. Musk, though both cases arose from an acquirer's refusal to close rather than a target's termination.²⁶

The narrower and more durable point is that the regulatory-likelihood prong calls for a genuine assessment of probability rather than a nominal acknowledgment that clearance is uncertain. The question was never adjudicated, the contest having ended by agreement, but it illustrates the tension between a board's incentive to capture auction value and the contractual machinery designed to protect a counterparty's bargained-for certainty. The same prong has an affirmative use as well: a target facing a risky interloper may condition its determination of superiority on the elimination or substantial reduction of the regulatory risk itself, whether by a hell-or-high-water commitment, a reverse termination fee sized to the harm, or clearance already in hand.²⁷

Transaction practice runs in the same direction. Interlopers that have prevailed over signed merger agreements have generally addressed the antitrust risk directly: by posing less antitrust risk than the incumbent's transaction, by removing the overlap through divestitures proposed as part of the offer itself, or by accepting a hell-or-high-water regulatory covenant. Where the bidder leaves the risk in place and merely prices it into its offer through prepaid consideration, ticking fees, and reverse termination fees, the stockholders bear the risk of an enjoined merger and an insolvent company.²⁸

Whether the transaction structure was preclusive. No Delaware court has considered whether a structure of the type proposed by Novo impermissibly precludes competing bids. Nor has any court reached that issue in this case, because Metsera and Novo never entered into a merger agreement, and Pfizer, although it litigated on several grounds, did not plead preclusion. No Delaware decision has treated a preferred redemption right or an obligation to buy out a predecessor bidder as a deal-protection device, so the analysis turns on analogy. That raises two questions: first, whether a right of this kind constitutes a deal-protection device at all, and second, if it does, whether the structure precluded competing bids. Both questions are worth addressing because the Metsera board determined on three occasions that Novo's proposal was superior, and the board would have needed to resolve them before terminating the Pfizer Agreement and entering into an agreement with Novo.

Novo's terms carried two protections, one conventional and one novel. The first was a package of fees: a $227 million termination fee plus reimbursement of the $190 million Pfizer termination fee Novo would have advanced at signing. The second was a mandatory redemption of the preferred stock Novo would hold, roughly $7.6 billion in cash. Taken alone, the termination fee came to just over two percent of the final headline value of approximately $10.0 billion, well within the customary range; taken together with the reimbursement, the cash a subsequent topping bidder would have had to fund came to roughly $417 million, about four percent of that final headline value, a figure at the high end of the customary range but conventional in form. The percentages are sensitive to the denominator: measured against an equity value that discounts the CVR as the illustration above does, the cash package approaches five percent, a figure between Topps and the band Comverge described as testing the limits of the range the Court of Chancery had found reasonable.²⁹

The redemption was the novel protection. A redemption right triggered by a change of control is among the most ordinary of preferred-stock exit terms and would, without more, raise no deal-protection concern. The certificate of designation required Metsera to redeem the preferred stock in cash at the price Novo had paid, the preference redemption price; and the obligation was self-executing at the closing of either of two transactions. The first was a topping-bid transaction, the agreement Metsera would enter into concurrently with a termination through the fiduciary out. The second was a covered subsequent transaction, an acquisition agreed to after a termination for failure to obtain the stockholder vote and struck within twenty-four months of the original signing, or within thirty-six months where discussions had begun in the first twenty-four. Those two closings are the covered exits. What distinguished this redemption were its departures from that ordinary form: a covered transaction could be struck long after the merger agreement had terminated, the triggers ran to the exits from the Novo bid as such, and the redemption returned Novo's cost in full and in cash, a form of payment that reduced what a rival could afford to pay the common stockholders and left the rival no practical way to pay solely in its own stock.³⁰

The certificate priced competition, and only competition, at cost, dividing the world by the manner of the transaction's failure. If Metsera had terminated to accept a superior proposal, the redemption was payable in cash at Novo's cost, with no election on either side. If the stockholders had voted the merger down and Metsera had then been sold within the windows the certificate fixed (the tail), a competing acquirer would have owed Novo the full, unadjusted redemption amount for a company then worth potentially far less, and Novo, whose election it was, could instead have taken the acquisition consideration on an as-converted basis,³¹ so the tail redemption paid the greater of cost and market. If the transaction had instead failed because of its antitrust infirmities, by injunction or by lapse at the outside date, a later sale would have redeemed the preferred at as-converted value. The fixed-price exposure thus sat on the exits by which Metsera's side could walk to a rival, while the regulatory-failure exits carried market-value redemption.³²

The redemption paid Novo nothing if Metsera's business failed, and it returned Novo's cost in full only where the company walked to a rival through the covered exits; it insured Novo against competition rather than against loss. The protections an investor bargains for as an investor (liquidation preferences, anti-dilution adjustments, and registration rights) guard against lost value and illiquidity, and none of them varies in amount with the route by which the company comes to be sold. The redemption terms therefore protected Novo's position as bidder rather than as investor, and functioned as a deal protection rather than an ordinary liquidity term.

Novo's purpose was not on that account illegitimate: a bidder that advances the entire cash portion of its price at signing may fairly protect itself against a rival that would free-ride on that upfront commitment, the stalking-horse logic under which Delaware sustains termination fees. But Delaware polices that logic by reference to size, tolerating protections calibrated to compensate the first bidder while rejecting those large enough to foreclose rivals. A recoupment right that, on a sale following a failed vote, could have returned roughly $7.6 billion in cash for a company then worth a fraction of that sum may belong to the foreclosing category.

Delaware law reviews deal-protection and defensive measures bearing on control for proportionality under Unocal and Unitrin, and, in a sale of control, for reasonableness under Revlon, frameworks that converge on the same prohibition: a measure may not operate as a preclusive or coercive bar to a superior alternative.³³ The governing formulation asks whether a measure renders a successful competing bid "mathematically impossible or realistically unattainable." Omnicare is the strongest, though much-debated, illustration of a protection struck down on that ground. Its facts are distinct: the lock-up in that transaction combined majority-stockholder voting agreements, a force-the-vote covenant under Section 251(c) (now 8 Del. C. § 146), and the absence of any fiduciary out; no single element would have sufficed, but together they precluded the possibility of any competing bid. The deterrent here was financial, and courts have generally been more tolerant of financial deterrents, such as fees and reimbursement obligations, than of structural voting lock-ups. That the redemption price was fixed at Novo's cost does not, without more, place the right outside the prohibition on preclusive measures, any more than pricing the option in QVC at the deal price immunized that option. The exercise price of that option matched the favored bid, yet the court held the option invalid because its value, uncapped and inflated by senior subordinated note and put features, grew as competing bids emerged, so that the more attractive the rival offer, the more the option cost the rival to defeat. The Novo redemption worked a similar deterrent through the opposite mechanism: the QVC option rose in price as a competing bid improved, and the Novo redemption held its price as Metsera's own value fell.

The facts as they developed offer only a weak test of whether the redemption obligation crossed the preclusion line: Pfizer matched the Novo Proposal before any Novo agreement was signed, so the redemption obligation never attached and no bidder ever had to fund it. The arithmetic nonetheless makes the concern precise. Novo's preferred represented fifty percent of Metsera's post-issuance fully diluted capital, for a subscription that Novo's own announcements valued at approximately $6.5 billion on the original terms and approximately $7.6 billion on the final terms. Together with the fees, the aggregate obligation on the final terms was roughly $8.0 billion, against an implied equity value of approximately $10.0 billion on the fully diluted count. The relevant comparison is between the all-in cost of a topping bid under the structure (the price of the post-Dividend common stock together with the redemption and the fees) and what a rival bidder would have had to pay to acquire all of Metsera's outstanding common stock, plus fees, had the preferred never been issued. At the price the contest ultimately reached, the two were approximately equal: the redemption returned to Novo the value of the half-interest it held, and the fees added the roughly $227 million by which the combined Novo termination fee and reimbursement obligation exceeded the $190 million Pfizer fee a topping bidder would have had to fund in any event. That approximate equality would not have held at a lower valuation, because, on the covered exits, the redemption price was fixed at Novo's cost and would not have declined if Metsera's value fell, whereas the price a rival would pay for the common stock would have declined with it. A rival would then have had to pay Novo's fixed redemption amount in cash as well as a potentially shrunken purchase price for the common stock, a package that raised financing risk.

Two figures describe the package, roughly $417 million and roughly $7.6 billion, and they measure different things. As a net economic cost the package is modest: the $417 million of fees, together with any excess of the redemption price over the value of the interest it retired, an excess of nothing at the final deal price and of several billion dollars at the depressed prices a failed vote and later sale could have involved. A sophisticated rival could in principle price the redemption into its own bid by reducing what it paid the common stockholders, but a discount borne by the common stockholders could frustrate their approval of the rival's transaction. As a financing requirement the package is of a different order: a topping bidder would have had to fund the $7.6 billion cash payment to buy Novo out while attempting to improve on Novo's price. No case holds the sheer magnitude of a financing requirement preclusive standing alone, and because the redemption would have retired a preferred interest representing half the fully diluted equity, at the final deal price any acquisition of the whole company would have required comparable financing. The concern is therefore better framed by the character of the obligation than by its scale: a purchase price fluctuates with the value of the company; on the covered exits this redemption did not, holding at $7.6 billion in cash regardless of what Metsera was then worth. A constraint of that character could reasonably be expected to deter bidders not already committed to a transaction of that scale, bidders that could not count on using their own stock to satisfy the redemption. That is the kind of deterrent the preclusion doctrine is designed to police, operating as a financing constraint while the deal price held and, once it did not, as a Comverge-style net-cost premium.

The fees and the redemption operated as a single package: a subsequent bidder proceeding through the covered exits would have had to fund the return of the entire cash portion Novo had already advanced, together with the fees, before improving on Novo's price. Comverge supplies the governing principle rather than a numerical threshold.³⁴ There the Court of Chancery declined to dismiss a preclusion claim where a termination fee and expense reimbursement, taken together with an acquirer-provided convertible note that raised the cost of a topping bid, could amount to roughly thirteen percent of equity value, in the context of a deal struck at a negative premium to market. What Comverge weighed was net cost, and on that footing the Novo package is not directly analogous: its roughly $7.6 billion is largely returnable, because the payment retires a preferred interest representing half the fully diluted equity rather than exacting a penalty above the deal price; and the Novo transaction carried a very large premium where the deal in Comverge carried a negative one. But Comverge's lesson remains instructive: an aggregate obligation a topping bidder must absorb can operate as a preclusive bar even where each component is individually defensible.

Because the package was never tested, the question of its proportionality remains open rather than resolved. Steven C. Salop reached the same economic conclusion within two weeks of the proposal, describing its terms as a 'heads I win, tails you lose" proposition in the register of exclusionary conduct rather than of fiduciary doctrine.³⁵ The structure illustrates how a device adopted to deliver certainty to one bidder can become an impediment to the competitive process that enhanced scrutiny exists to protect. The relevant question is what the package would have done to an equally motivated but less well-funded competing bidder, which would have had to fund the redemption and absorb its effect on what it could offer the common stockholders.

Whether the Dividend was lawful. This further question is separate from the board's conduct and the deal-protection terms, resting instead on Delaware's legal-capital (capital-maintenance) rules; it is noted here but not addressed.³⁶

The Effect on Metsera's Stockholders

The auction benefited the stockholders; the structure, standing alone, did not. Measured against the world in which Novo did not intervene, Metsera's stockholders were plainly better off. Competitive tension drove Pfizer from its initial $70.00 to a final agreement of up to $86.25 per share ($65.60 in cash and a CVR of up to $20.65),³⁷ weighted more heavily toward cash and thus toward certain value, and the stockholders obtained that increase with the high closing certainty of an acquirer presenting no antitrust impediment. As negotiating leverage, the Novo Proposal served the stockholders well.

Assessed on its own terms, however, the proposal Metsera's board three times found superior was, on a risk-adjusted basis, the weaker of the two, for the reasons the illustration above makes explicit. That the stockholders fared well owes principally to the competitive process rather than to the soundness of the structure.

Practice Points

• Price the antitrust risk explicitly, using the probability-and-spread framework rather than the face-times-probability shorthand. The risk tends to be largest for market leaders, and where competing bids converge in amount and composition, it is often the entire basis of comparison; a high unaffected price narrows the discount, and a long expected timeline deepens it.
• Stress-test any structure that front-loads consideration against applicable premerger-notification regimes and their anti-avoidance doctrines before crediting its "certainty." A payment that delivers the economic substance of an acquisition before clearance may be disregarded under the avoidance rule discussed above, and interim operating covenants that exceed value preservation invite gun-jumping exposure; the certainty such a structure promises is only as good as its ability to survive judicial scrutiny. The principle is not confined to this transaction: front-loaded acqui-hire arrangements, minority investments that confer economic rights disproportionate to their voting interest, and other structures that disaggregate an acquisition into nominally exempt steps are now subject to the same avoidance-rule inquiry. Where the applicability of an exemption is genuinely close, the disciplined course is to obtain an informal staff view from the FTC's Premerger Notification Office before proceeding, or to file protectively and absorb the waiting period, rather than rely on an exemption opinion alone. A staff view binds no one, but it sharpens the probability assessment; if the parties nonetheless proceed without seeking one, they should document that choice as a considered judgment rather than leave it as an unexamined assumption.
• Make and document "superior proposal" determinations with the regulatory-likelihood prong assessed probabilistically. A determination that a competing bid constitutes a superior proposal because it offers a higher price, without a probabilistic assessment of the likelihood that the transaction will fail to close for regulatory reasons, is vulnerable both as a matter of contract with the existing counterparty and as a matter of process. A board that builds a record supporting a superior-proposal finding while simultaneously recording unacceptable risk in the same bid constrains its own options: it becomes harder to accept the bid without exposing the legal risk identified, and harder to decline it without explaining why the superiority finding was overstated. The sequencing, timing, and framing of the board's findings, rather than the suppression of any of them, can matter as much as the deal terms. The converse also holds: a target may define superiority to require that the bidder eliminate or substantially reduce the regulatory risk, whether by a hell-or-high-water commitment, by pre-clearance, or by a reverse termination fee sized to the harm, before its proposal qualifies.
• Analyze predecessor-bidder buyout obligations for preclusion risk under enhanced scrutiny, and distinguish net cost from financing magnitude. The question is distinct from the one an ordinary termination fee or expense reimbursement raises: it arises only where an earlier bidder holds an equity or quasi-equity position in the target that a topping bidder must retire before closing. The operative concern is whether the aggregate sum a topping bidder must absorb to fund that buyout is itself a financing constraint that forecloses an equally motivated but less well-capitalized rival. The features that bear on that judgment are whether the trigger runs to the competing-bid exits as such rather than to a change of control generally, whether the price is fixed at the first bidder's cost or moves with the target's value, whether a tail extends the obligation beyond termination of the agreement, whether the obligation can be satisfied in the topping bidder's own stock, whether it approaches the target's standalone equity value, and whether its cost can be recovered from the common stockholders without jeopardizing their approval of the rival's transaction. That the package went untested in Metsera does not establish its proportionality.
• Integrate the corporate and antitrust analyses, and engage both corporate and antitrust counsel, from the earliest stage of structuring. A structure that is elegant on the corporate and stockholder-value axis can be fatal on the antitrust axis. Condition any commitment on a preliminary assessment of premerger-notification exposure. The contest illustrates what sequencing these inquiries too late can cost: the Court of Chancery denied Pfizer emergency relief without finally adjudicating the contract claims, and the Novo Proposal failed on the convergence of the FTC staff's avoidance-rule objection and a fully matched topping bid rather than on a judicial determination of its substance.

_{1 Section 9.1 of the certificate of designation, as set out in the proposed Novo merger agreement, qualified the cash character of the redemption without changing it in practice. On the closing of a topping bid in connection with a termination for a superior proposal, there was no election on either side: the redemption was cash, at Novo’s cost. Only in a covered subsequent transaction could the holder elect to take instead what the common stockholders were receiving, in kind and in amount, on an as-converted basis. Even then, if part of that consideration was non-cash and the holder still could not lawfully receive it after filing under the HSR Act and waiting thirty days (as would be so, for example, if the filing drew a second request), the holder took cash at the fair market value of that portion unless the holder chose to take the further steps needed to receive it. The election was Novo’s alone. A competing bidder therefore could not plan to satisfy the redemption in its own stock; and had Novo elected stock and cleared review, the bidder would have bought the company with its former rival as a continuing stockholder, an outcome no acquirer would welcome. In practice, then, the obligation was a cash obligation, payable in stock only if Novo so chose.
2 Agreement and Plan of Merger, dated September 21, 2025, among Pfizer Inc., Mayfair Merger Sub, Inc., and Metsera, Inc. (filed as Exhibit 2.1 to Metsera’s Current Report on Form 8-K (September 22, 2025)). The original consideration was $47.50 per share in cash plus a contingent value right of up to $22.50 per share. Metsera’s November 4, 2025, press release (Exhibit 99.1 to the Form 8-K of that date) stated the revised Pfizer proposal’s $70.00 package as a total of approximately $8.1 billion; Pfizer’s announcement stated an enterprise value of approximately $4.9 billion for the cash component. The parties filed under the HSR Act on October 8, 2025, and the FTC granted early termination on October 31, 2025 (Early Termination Notice No. 20260047); see Pfizer Inc., Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition (October 31, 2025). Matching right and termination fee: Pfizer Agreement §§ 5.02(e), 8.02(b).
3 The Novo proposal is described in Metsera’s Current Reports on Form 8-K (October 30 and November 4, 2025); the proposed agreement and plan of merger was filed as Exhibit 99.2 to the October 30 report. The October 30 proposal comprised $56.50 in cash upfront and a CVR of up to $21.25; Novo raised to $62.20 and $24.00 on November 4 and to $65.60 and $20.65 on November 6, its announcements valuing the upfront subscription at approximately $6.5 billion, $7.2 billion, and $7.6 billion, respectively. Novo issued no standalone November 6 announcement; its November 8 release recites the November 6 terms. The bid-by-bid chronology (including Pfizer’s November 3 revised offer and its conditions) and the board’s determinations are set out in Metsera’s proxy supplement (Schedule 14A, filed November 10, 2025) and in Novo’s announcements of October 30 and November 8, 2025.
4 The HSR Act conditions premerger notification on acquisitions of voting securities or assets above the applicable thresholds. 15 U.S.C. § 18a. The implementing rules define "voting securities" to include securities that presently entitle the holder to vote for directors or, in the case of convertible securities, that will entitle the holder to vote upon conversion. 16 C.F.R. § 801.1(f)(1)(i). Non-voting stock that is not convertible into voting securities falls outside the definition. Convertible non-voting stock is within it, but its acquisition is exempt from the notification requirement under § 802.31; conversion is itself a separate, potentially reportable acquisition. See id. §§ 801.32, 802.31. The related inquiry into beneficial ownership is governed by id. § 801.1(c); the indicia of beneficial ownership (the rights, benefits, and risks incident to ownership) derive from the Statement of Basis and Purpose, 43 Fed. Reg. 33,450, 33,458 (July 31, 1978), and the Premerger Notification Office’s interpretations, which look to the substance of the rights acquired rather than to the form of the instrument.
5 The framework in the text has a long antecedent in risk arbitrage, which priced announced transactions in the same terms before the poison pill and mandatory premerger review defined the modern interval between signing and closing; those two developments moved the assessment from the arbitrageur’s trading decision to the board’s superior-proposal determination, where the contract now places it. Goldman Sachs conducted the business under Gustave Levy; Robert E. Rubin, who later led the department, describes its method in his memoir. See Robert E. Rubin & Jacob Weisberg, In an Uncertain World: Tough Choices from Wall Street to Washington 41–46 (2003). The canonical practitioner statement is Warren E. Buffett’s Chairman’s Letter in Berkshire Hathaway’s 1988 annual report (1989), which asks four questions of an announced deal: the likelihood the event occurs, the time the capital will be committed, the chance that something better transpires, and the consequence if it fails, the letter’s first example of failure being "anti-trust action." For the demonstration that target prices impound completion probabilities, see William Samuelson & Leonard Rosenthal, Price Movements as Indicators of Tender Offer Success, 41 J. Fin. 481 (1986); on the risk and return of the strategy, Mark Mitchell & Todd Pulvino, Characteristics of Risk and Return in Risk Arbitrage, 56 J. Fin. 2135 (2001). The poison pill dates from 1982 to 1983 and was sustained in Moran v. Household Int’l, Inc., 500 A.2d 1346 (Del. 1985); the HSR premerger notification rules took effect in 1978.
6 Proposed Agreement and Plan of Merger (Novo) § 8.01(b)(i). The defined term is the "Termination Date"; the Initial Termination Date fell twenty-four months after signing, and Novo alone could extend it, in two steps, to twenty-seven and then thirty months. Pfizer’s Court of Chancery complaint described the proposal’s "27-month outside date" as "one of the longest outside dates ever included in a merger agreement"; its federal complaint used the fully extended thirty months; the illustration uses the thirty-month horizon.
7 15 U.S.C. § 18.
8 The "killer acquisition" label is from Colleen Cunningham, Florian Ederer & Song Ma, Killer Acquisitions, 129 J. Pol. Econ. 649 (2021).
9 Metsera’s Current Report on Form 8-K (November 10, 2025), Exhibit 99.1; proxy supplement (definitive additional materials on Schedule 14A, filed November 10, 2025). The amendment-related filings are dated November 7 and were filed November 10, 2025; the board’s findings and the November chronology are recited in the proxy supplement of that date.
10 Reading the probability cell: the Novo back end pays only if two events occur in sequence. The upfront structure must survive the avoidance-rule challenge (assumed 75%), and, given survival, the back-end acquisition must clear Section 7 review and close (assumed 60%). The unconditional probability that the back end pays is therefore 0.75 × 0.60 = 0.45. The risk-adjusted figure aggregates three scenarios: failure of the structure, with the Dividend not retained (25%), in which stockholders revert to the unaffected price; survival with clearance (45%), in which stockholders keep the upfront cash and receive the CVR, valued at the outside date; and survival without clearance (30%), in which stockholders keep the cash and hold common stock assumed to retain roughly half the unaffected price, reflecting the preferred’s half interest, discounted from the outside date. The table’s CVR line is likewise valued at the outside date, although the milestone schedule runs to 2031.
11 The consideration figures are those disclosed by the parties; the premiums and the September 19, 2025, unaffected reference price are drawn from Metsera’s Current Reports on Form 8-K. The discount rate, the CVR realization rate, and the probabilities are the author’s assumptions, included to make the variables explicit rather than to predict an outcome. Closing prices are from Nasdaq trading history: $33.32 on September 19 (the unaffected close); $73.18 on November 4; $70.87 on November 10, 2025.
12 Pfizer completed the acquisition on November 13, 2025, for $65.60 per share in cash plus a contingent value right of up to $20.65 per share. Pfizer Inc., Pfizer Completes Acquisition of Metsera (November 13, 2025). The Pfizer Agreement § 8.01(b)(i) set an outside date of March 21, 2026, extendable to June 21, 2026.
13 16 C.F.R. § 801.90.
14 United States v. Canon Inc., No. 1:19-cv-01680 (D.D.C. June 10, 2019) (complaint and proposed final judgment; civil penalty of $2.5 million against each party for a Hart-Scott-Rodino Rule 801.90 avoidance device; filed by the Department of Justice on a referral from the FTC). The European Commission imposed a separate fine of €28 million for gun-jumping under Articles 4(1) and 7(1) of the EU Merger Regulation. Canon/Toshiba Medical Systems Corp., Case M.8179 (June 27, 2019), appeal dismissed, Case T-609/19, Canon Inc. v. Commission (Gen. Ct. May 18, 2022). China’s Ministry of Commerce (MOFCOM) fined Canon RMB 300,000 (December 2016), and Japan’s Fair Trade Commission cleared the transaction while cautioning that the structure might not satisfy its notification requirements. For the avoidance-rule principle, see FTC, Competition Matters, Avoidance Devices Won’t Avoid HSR Penalties (November 14, 2019); Seeing the Whole Picture on Avoidance Devices (September 23, 2020). For commentary on the present transaction, see Steven C. Salop, Novo Nordisk’s Killer Non-Acquisition Merger Contract Proposal Is a Case of "Heads I Win, Tails You Lose," ProMarket (November 11, 2025); Wachtell, Lipton, Rosen & Katz, Mergers and Acquisitions—Reviewing 2025 and Looking Ahead to 2026 (December 17, 2025), and Takeover Law and Practice 2026 (May 2026); and Goodwin, Antitrust and Competition Life Sciences Year in Review 2025 (February 5, 2026). Professor Ann M. Lipton drew the Canon/Toshiba analogy within days of the proposal’s disclosure, as quoted in John Jenkins, Deal Jumping: Novo Nordisk & Pfizer & Metsera – Oh My!, DealLawyers.com (November 3, 2025); see also Lipton, Sideways, Business Law Prof Blog (November 6, 2025). On the rule’s application beyond this deal, see Herbert Smith Freehills Kramer, When Is a Transaction That Avoids HSR a Transaction for Avoidance? (May 2026), discussing Rule 801.90 in connection with the NVIDIA/Groq transaction and related congressional inquiries. The only other academic treatment to date, Lior Frank, "Strategic Preemptive Acquisitions" in the Lens of Corporate and Antitrust Laws—Following the Pfizer-Novo-Metsera Dispute, Mich. St. L. Rev. Online (April 2026), does not reach the deal-protection question addressed below.
15 Letter from Daniel Guarnera, Director, Bureau of Competition, FTC, to counsel for Novo and Metsera (November 4, 2025); the letter is described in Metsera’s proxy supplement and quoted in the commentary cited supra note 14. Pfizer’s Chancery action was Pfizer Inc. v. Metsera, Inc., C.A. No. 2025-1259-MTZ (Del. Ch.). After hearings on November 4 and 5, 2025, the court denied the application from the bench on November 5, without finally adjudicating the contract claims; there is no written opinion. For reported remarks at the November 4 hearing, see Reuters, Delaware Judge Does Not See Current Need for Court in Metsera Bidding War Between Pfizer and Novo (November 4, 2025). For the bench ruling denying the application, see Metsera’s proxy supplement (Schedule 14A, filed November 10, 2025) ("At the conclusion of the November 5, 2025 hearing, the Court ruled from the bench in favor of the Company and denied the TRO."). Pfizer also filed a federal antitrust action, Pfizer Inc. v. Novo Nordisk A/S, No. 1:25-cv-01339 (D. Del. Nov. 3, 2025) (Clayton Act § 7; Sherman Act §§ 1, 2); both actions were dismissed by stipulation in February 2026.
16 See 15 U.S.C. § 18; United States v. E.I. du Pont de Nemours & Co., 353 U.S. 586 (1957); United States v. Dairy Farmers of America, Inc., 426 F.3d 850 (6th Cir. 2005).
17 15 U.S.C. § 18a(g)(1) (daily civil penalties), (g)(2) (equitable relief); 15 U.S.C. § 1; see United States v. Comput. Assocs. Int’l, Inc., No. 1:01CV02062, 2002-2 Trade Cas. (CCH) 73,883 (D.D.C. 2002); United States v. Flakeboard Am. Ltd., No. 3:14-cv-04949 (N.D. Cal. 2014) ($3.8 million in HSR civil penalties, comprising $1.9 million from each of the two parties, plus $1.15 million of Sherman Act disgorgement from Flakeboard, the two doctrines operating in a single case). See supra note 15. Neither doctrine supplies a numerical safe harbor; the defensibility of a consent threshold is relational rather than absolute, the figure being measured against the target’s own budgeted spending and its stage of development, so that a cap pitched above budgeted research and clinical expenditure is ordinarily defensible, whereas one low enough to capture routine pipeline spending operates as a veto over the ordinary conduct of the business. The same distinction governs personnel covenants: undertakings not to alter compensation outside the ordinary course, or undertakings to obtain the acquirer’s consent before appointing or removing senior executives, are conventional preservation terms, whereas covenants permitting the acquirer to direct or to veto the retention of scientific staff, or operating between competitors as a no-poach or wage-fixing arrangement, are not, the latter raising a Section 1 problem independent of the notification rules.
18 See, e.g., FTC v. Steris Corp., 133 F. Supp. 3d 962 (N.D. Ohio 2015) (preliminary injunction denied); FTC v. Meta Platforms, Inc., 654 F. Supp. 3d 892 (N.D. Cal. 2023) (same, after which the FTC abandoned the challenge). The record is mixed in both directions: the agencies have also prevailed by abandonment, see In re Sanofi/Maze Therapeutics, Inc., FTC Docket No. 9422 (complaint issued December 11, 2023; transaction abandoned), and United States v. Visa Inc., No. 3:20-cv-07810 (N.D. Cal. filed Nov. 5, 2020) (abandoned January 2021); and on the merits, though on a vertical rather than nascent-competition theory, see Illumina, Inc. v. FTC, 88 F.4th 1036 (5th Cir. 2023) (sustaining the Commission’s competitive-effects analysis while vacating and remanding on the standard applied to Illumina’s rebuttal).
19 See supra note 9. The board’s determination quoted in the text is recited in the proxy supplement (Schedule 14A, November 10, 2025).
20 Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., 506 A.2d 173 (Del. 1986); Paramount Commc’ns Inc. v. QVC Network Inc., 637 A.2d 34 (Del. 1994); see also Lyondell Chem. Co. v. Ryan, 970 A.2d 235 (Del. 2009).
21 Proposed Agreement and Plan of Merger (Novo) § 5.02(c)(ii); Pfizer Agreement § 5.02(h).
22 Corwin v. KKR Financial Holdings LLC, 125 A.3d 304 (Del. 2015).
23 The "control group" and "controlling stockholder" definitions are 8 Del. C. § 144(e)(1) and (e)(2); "controlling stockholder transaction" is defined in § 144(e)(3); the safe harbors are § 144(b) and (c). The amendments were upheld against constitutional challenge in Rutledge v. Clearway Energy Grp. LLC, No. 248, 2025, 2026 WL 548504 (Del. Feb. 27, 2026). Had the Novo transaction been consummated, the indemnification of the principal stockholders could have been argued to bring the sale within the benefit prong of § 144(e)(3); because it was not, the point is academic.
24 8 Del. C. § 102(b)(7).
25 On the first path, the board’s choice would have been protected not only by Corwin, but by the settled rule that a board may prefer a more certain transaction to a higher but riskier one. See In re Family Dollar Stores, Inc. S’holder Litig., 2014 WL 7246436 (Del. Ch. Dec. 19, 2014) ("a financially superior offer on paper does not equate to a financially superior transaction in the real world if there is a meaningful risk that the transaction will not close for antitrust reasons"); In re Dollar Thrifty S’holder Litig., 14 A.3d 573 (Del. Ch. 2010); In re BJ’s Wholesale Club, Inc. S’holders Litig., 2013 WL 396202 (Del. Ch. Jan. 31, 2013) (dismissing Revlon claims where the board preferred a firm bid over a higher indication of interest). Any residue under Lyondell, which confines such liability to bad faith or a conscious abdication of duty, would have been defeated by an advice-of-counsel record finding the Novo Proposal’s legal and regulatory risk unacceptable. On the second path, the same advice-of-counsel finding would have cut the other way, handing Pfizer the evidence that the Novo Proposal never carried the deliverability the superior-proposal definition required, so that the resulting damages would have sounded in contract rather than fiduciary duty.
26 Pfizer Agreement § 8.02(a), (c); Consolidated Edison, Inc. v. Northeast Utilities, 426 F.3d 524 (2d Cir. 2005); Crispo v. Musk, 304 A.3d 567 (Del. Ch. 2023).
27 Delaware has sustained boards that made elimination of the risk the price of superiority. Family Dollar’s board declined a nominally higher bid carrying a $500 million reverse termination fee and a divestiture commitment capped at 1,500 stores, its advisors assessing approval odds at roughly forty percent; Dollar Thrifty’s board was sustained in treating a rival’s refusal to offer a reverse termination fee as weighing decisively against superiority; for both decisions, see supra note 25. The available conditions run from hell-or-high-water and specified-divestiture commitments, to a reverse termination fee sized to the harm with a ticking fee for the delay, to clearance obtained before superiority attaches. The Metsera contest contains the tactic in both directions: the board used the competing bid as leverage without terminating, and Pfizer’s November 3 revised offer demanded that Metsera publicly declare the rival proposal unviable.
28 An instructive example is Boston Scientific’s January 2006 offer for Guidant Corporation, which prevailed over Guidant’s signed agreement with Johnson & Johnson and was delivered together with a binding agreement, executed the same day for the stated purpose of securing antitrust clearance, to divest Guidant’s vascular intervention and endovascular businesses to Abbott Laboratories. The cautionary example of pricing the risk is JetBlue’s agreement to acquire Spirit Airlines, which prevailed over Spirit’s signed agreement with Frontier through a package that included a $2.50-per-share prepayment upon stockholder approval, a ticking fee of $0.10 per share per month, and a $470 million reverse termination fee. The merger was enjoined under Section 7, United States v. JetBlue Airways Corp., 712 F. Supp. 3d 109 (D. Mass. 2024); the parties terminated their agreement in March 2024; and Spirit commenced chapter 11 proceedings that November, In re Spirit Airlines, Inc., No. 24-11988 (SHL) (Bankr. S.D.N.Y. Nov. 18, 2024), followed by a second filing in August 2025. For systematic evidence on how deals die and on the choice between price and certainty, see Da Lin & Morgan Ricks, How Deals Die, 93 U. Chi. L. Rev. 867 (2026).
29 Fees sustained include three percent of equity value in In re Cogent, Inc. S’holder Litig., 7 A.3d 487 (Del. Ch. 2010), where the court measured the fee against equity rather than enterprise value; 3.75 percent in In re Toys "R" Us, Inc. S’holder Litig., 877 A.2d 975 (Del. Ch. 2005); and around 4.3 percent of total deal value (including expense reimbursement) in In re Topps Co. S’holders Litig., 926 A.2d 58 (Del. Ch. 2007). The outer markers are In re Comverge, Inc. S’holders Litig., 2014 WL 6686570 (Del. Ch. Nov. 25, 2014) (combined fees of 5.55 to 7 percent of equity value "test[] the limits" of the reasonable range), and Phelps Dodge Corp. v. Cyprus Amax Minerals Co., 1999 WL 1054255 (Del. Ch. Sept. 27, 1999) (6.3 percent "seem[s] to stretch the definition of range of reasonableness . . . beyond its breaking point").
30 Nor could Metsera have funded the redemption from its own resources. It reported cash and cash equivalents of approximately $448.5 million at September 30, 2025, against a redemption obligation that on the final terms came to roughly $7.6 billion. Metsera, Inc., Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (condensed consolidated balance sheet).
31 Certificate of Designation of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock, Exhibit B to the proposed Novo merger agreement (Exhibit 99.2 to Metsera’s Form 8-K of October 30, 2025), § 9.1. The election belonged to the holder and arose only upon a "Subsequent Transaction"; upon the closing of a "Topping Bid Agreement," the certificate required redemption in cash at the "Preference Redemption Price," with no election on either side. For the mechanics of the election, see supra note 1.
32 Certificate of Designation §§ 9.1, 9.2, 9.5. The at-cost redemption attaches to the closing of a topping-bid transaction entered into concurrently with a fiduciary-out termination under Section 8.01(d)(ii) of the proposed agreement and to a "Subsequent Transaction" following a termination for failure of the stockholder vote under Section 8.01(b)(iii); every other covered acquisition is a "Fundamental Transaction" redeemed at as-converted value. Metsera’s Form 8-K summarized the tail as running "[u]ntil the third anniversary of the termination," a formulation the certificate does not contain; its windows run from signing.
33 Unocal Corp. v. Mesa Petroleum Co., 493 A.2d 946 (Del. 1985) (defensive measures must be reasonable in relation to the threat posed); Unitrin, Inc. v. American General Corp., 651 A.2d 1361 (Del. 1995) (measures may not be preclusive or coercive) (the "mathematically impossible or realistically unattainable" formulation, framed there for proxy-contest viability and since applied as the general preclusiveness standard, Versata Enters., Inc. v. Selectica, Inc., 5 A.3d 586 (Del. 2010)); Omnicare, Inc. v. NCS Healthcare, Inc., 818 A.2d 914 (Del. 2003) (invalidating a fully locked-up merger structure); In re Toys "R" Us, Inc. S’holder Litig., 877 A.2d 975 (Del. Ch. 2005) (sustaining a market-standard package of matching rights and a termination fee); In re Cogent, Inc. S’holder Litig., 7 A.3d 487 (Del. Ch. 2010) (sustaining matching rights and a termination fee within the customary range).
34 Comverge, 2014 WL 6686570 (declining to dismiss a challenge to the aggregate cost of a termination fee and expense reimbursement coupled with an acquirer-held note convertible below the deal price; the fees alone, at 5.55 to 7 percent of equity value, were said to "test[] the limits" of the reasonable range).
35 Salop, supra note 14.
36 A dividend may be paid only out of surplus or, in limited circumstances, net profits. 8 Del. C. § 170(a). Surplus is defined in 8 Del. C. § 154 as the excess of net assets over stated capital, and directors who pay an unlawful dividend are jointly and severally liable under 8 Del. C. § 174. The question turned on whether Metsera had sufficient surplus at the declaration date. See Klang v. Smith’s Food & Drug Ctrs., Inc., 702 A.2d 150 (Del. 1997) (a board may rely on a good-faith revaluation of assets to establish surplus). On the structuring of extraordinary distributions funded by concurrent investment proceeds, see generally Jack S. Levin & Donald E. Rocap, Structuring Venture Capital, Private Equity, and Entrepreneurial Transactions (Wolters Kluwer 2025).
37 Amendment No. 1 to the Pfizer Agreement (November 7, 2025). See Metsera’s Current Report on Form 8-K (November 10, 2025). The amendment increased the Company Termination Fee from $190 million to $265 million, replaced Pfizer’s $1.5 billion CVR-product development spending obligation with a covenant to use commercially reasonable efforts, and included mutual releases effective at closing. Stockholders approved on November 13, 2025 (99.98 percent of votes cast); the merger closed the same day.}

_{White & Case means the international legal practice comprising White & Case LLP, a New York State registered limited liability partnership, White & Case LLP, a limited liability partnership incorporated under English law and all other affiliated partnerships, companies and entities.}

_{This article is prepared for the general information of interested persons. It is not, and does not attempt to be, comprehensive in nature. Due to the general nature of its content, it should not be regarded as legal advice.}

_{© 2026 White & Case LLP}